Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Bristol Myers Squibb
Pharma
ASH: Adcetris, Opdivo boost hopes for another ADC, PD-1 combo
Seagen trotted out new data suggesting its ADC Adcetris could work with BMS' PD-1 drug Opdivo in two classical Hodgkin lymphoma settings.
Angus Liu
Dec 10, 2023 7:30pm
ASH: Study digs into FDA adverse event record of BCMA therapies
Dec 9, 2023 11:54am
BMS says goodbye to its top dealmaker Elizabeth Mily
Dec 8, 2023 11:25am
BMS's Opdivo-Yervoy excels in first-line colorectal cancer trial
Dec 7, 2023 10:53am
FDA probes CAR-T therapies' 'serious risk' of secondary cancer
Nov 28, 2023 1:16pm
CEOs of J&J, Merck, BMS called to testify on drug prices
Nov 21, 2023 3:02pm
